MODERNA: Tal Zaks 2017 TEDx Talk Promoting "GENE EDITING" mRNA Vaccines
Harold Saive
Moderna TEDx Talk: mRNA Vaccine Technology
(PROMOTION VIDEO 2017)
https://youtu.be/AHB2bLILAvM
Moderna TEDx Talk: mRNA Vaccine Technology (PROMOTION VIDEO
2017)
Tal Zaks from Moderna sells you the mRNA Vaccine
technology used in the COVID-19 "vaccines" a.k.a experimental
gene therapies. He proudly promotes they are "hacking the
software of life" and they call it "information therapy". They
see the body "as an operating system" to reprogram and he
admits TWICE that they don't know if it's going to work. Not
one single product ever approved for use because of its
dangers and the COVID-19 "vaccines" are for emergency use
only. This is a version with improved subtitles, pointing out
IN CAPS the most interesting things he says.
https://www.brighteon.com/3f1e4cd4-7fe8-43a2-868a-8732731e2ab6
TEDx Program
https://www.ted.com/about/programs-initiatives/tedx-program
The War on Cancer has been raging for over a century, and Tal
Zaks may have the biggest breakthrough yet. His idea, to go
straight to the source of the problem and edit the genetic
code that causes the body to produce cancerous cells,
could save millions of lives without a single surgery or
chemotherapy regimen. Tal Zaks is the Chief Medical Officer of
Moderna Therapeutics.
Tal Zaks is the Chief Medical Officer of Moderna Therapeutics.
This talk was given at a TEDx event using the TED conference
format but independently organized by a local community. Learn
more at https://www.ted.com/tedx
============================
Preclinical and Clinical Demonstration of Immunogenicity by
mRNA Vaccines against H10N8 and H7N9 Influenza Viruses (2017)
Kapil Bahl,1 Joe J. Senn,2 Olga Yuzhakov,1 Alex Bulychev,2
Luis A. Brito,2 Kimberly J. Hassett,1 Michael E. Laska,2 Mike
Smith,2 Örn Almarsson,2 James Thompson,2 Amilcar (Mick)
Ribeiro,1 Mike Watson,1 Tal Zaks,2 and Giuseppe Ciaramella1
(Published online 2017 Apr 27)
Recently, the World Health Organization confirmed 120 new
human cases of avian H7N9 influenza in China resulting in 37
deaths, highlighting the concern for a potential pandemic
and the need for an effective, safe, and high-speed vaccine
production platform. Production speed and scale of
mRNA-based vaccines make them ideally suited to impede potential
pandemic threats. Here we show that lipid nanoparticle
(LNP)-formulated, modified mRNA vaccines, encoding hemagglutinin
(HA) proteins of H10N8 (A/Jiangxi-Donghu/346/2013) or H7N9
(A/Anhui/1/2013), generated rapid and robust immune responses in
mice, ferrets, and nonhuman primates, as measured by
hemagglutination inhibition (HAI) and microneutralization (MN)
assays. A single dose of H7N9 mRNA protected mice from a lethal
challenge and reduced lung viral titers in ferrets. Interim
results from a first-in-human, escalating-dose, phase 1 H10N8
study show very high seroconversion rates, demonstrating
robust prophylactic immunity in humans. Adverse events
(AEs) were mild or moderate with only a few severe and no
serious events. These data show that LNP-formulated,
modified mRNA vaccines can induce protective immunogenicity with
acceptable tolerability profiles.
Keywords: mRNA vaccines, influenza, immunogenicity,
pandemic, vaccines, H10N8, H7N9, mRNA
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475249/
See TOWN SQUARE NEWS Updates: https://groups.google.com/g/town-square-news
